Advertisement
Screener

ABBOTT LABORATORIES (ABT) Graph

ABT Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-03-31: Revenue $11.16B; Cost of revenue $4.89B; Research and development $767.00M; Selling, general and administrative $3.74B.
  • 2025-12-31: Revenue $11.46B*; Cost of revenue $4.92B*; Research and development $735.00M*; Selling, general and administrative $3.13B*.
  • 2025-09-30: Revenue $11.37B; Cost of revenue $5.08B; Research and development $766.00M; Selling, general and administrative $3.05B.
  • 2025-06-30: Revenue $11.14B; Cost of revenue $4.85B; Research and development $725.00M; Selling, general and administrative $3.09B.

Consolidation item

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ABT revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Corporate Non Segment$5.00MOperating Segments$12.59BRevenue$12.59BCost of revenue$5.32BOperating income$1.69BOther income, net$134.00MResearch & development$892.00MSelling, general& administrative$4.02BPre-tax income$1.52BIncome tax$596.00MNet income$928.00M

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ABT revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Non Us$7.38BUS$5.22BRevenue$12.59BCost of revenue$5.32BOperating income$1.69BOther income, net$134.00MResearch & development$892.00MSelling, general& administrative$4.02BPre-tax income$1.52BIncome tax$596.00MNet income$928.00M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-03-31$11.16B$4.89B$767.00M$3.74B$372.00M$1.08B
2025-12-31$11.46B*$4.92B*$735.00M*$3.13B*$582.00M*$1.78B*
2025-09-30$11.37B$5.08B$766.00M$3.05B$536.00M$1.64B
2025-06-30$11.14B$4.85B$725.00M$3.09B$371.00M$1.78B
2025-03-31$10.36B$4.47B$716.00M$3.06B$453.00M$1.32B
2024-09-30$10.63B$4.70B$713.00M$2.90B$294.00M$1.65B
2024-06-30$10.38B$4.60B$698.00M$2.94B$305.00M$1.30B
2024-03-31$9.96B$4.46B$684.00M$2.96B$211.00M$1.23B
2023-09-30$10.14B$4.61B$672.00M$2.72B$235.00M$1.44B
2023-06-30$9.98B$4.48B$715.00M$2.74B$261.00M$1.38B
2023-03-31$9.75B$4.33B$654.00M$2.76B$244.00M$1.32B
2022-09-30$10.41B$4.63B$782.00M$2.73B$323.00M$1.44B
2022-06-30$11.26B$4.93B$684.00M$2.76B$334.00M$2.02B
2022-03-31$11.89B$4.99B$697.00M$2.79B$429.00M$2.45B
2021-09-30$10.93B$4.42B$672.00M$2.77B$393.00M$2.10B
2021-06-30$10.22B$4.95B$654.00M$2.73B$159.00M$1.19B
2021-03-31$10.46B$4.40B$654.00M$2.78B$250.00M$1.79B
2020-09-30$8.85B$3.97B$580.00M$2.30B$189.00M$1.23B
2020-06-30$7.33B$3.26B$564.00M$2.28B-$11.00M$537.00M
2020-03-31$7.73B$3.28B$578.00M$2.55B$89.00M$564.00M
2019-12-31$8.31B(m)(m)(m)(m)$1.05B
2019-09-30$8.08B$3.36B$596.00M$2.44B$143.00M$960.00M
2019-06-30$7.98B$3.28B$577.00M$2.43B$96.00M$1.01B
2019-03-31$7.54B$3.16B$672.00M$2.48B-$40.00M$672.00M
2018-12-31$7.76B(m)(m)(m)(m)$654.00M
2018-09-30$7.66B$3.17B$574.00M$2.38B$166.00M$563.00M
2018-06-30$7.77B$3.28B$575.00M$2.47B$59.00M$733.00M
2018-03-31$7.39B$3.07B$589.00M$2.54B$22.00M$418.00M
2017-12-31$7.59B(m)(m)(m)(m)-$828.00M
2017-09-30$6.83B$2.88B(m)$2.12B$65.00M$603.00M
2017-06-30$6.64B$3.19B(m)$2.15B$25.00M$283.00M
2017-03-31$6.33B(m)(m)$2.44B$350.00M$419.00M
2016-12-31$5.33B(m)(m)(m)(m)$798.00M
2016-09-30$5.30B(m)(m)$1.63B$178.00M-$329.00M
2016-06-30$5.33B(m)(m)$1.74B$116.00M$615.00M
2016-03-31$4.88B(m)(m)$1.70B-$54.00M$316.00M
2015-12-31$5.19B(m)(m)(m)(m)$767.00M
2015-09-30$5.15B(m)(m)$1.67B$118.00M$580.00M
2015-06-30$5.17B(m)(m)$1.73B$200.00M$784.00M
2015-03-31$4.90B(m)(m)$1.74B$124.00M$2.29B
2014-12-31$5.36B(m)(m)(m)(m)$905.00M
2014-09-30$5.08B(m)(m)$1.59B$277.00M$538.00M
2014-06-30$5.06B(m)(m)$1.65B$233.00M$466.00M
2014-03-31$4.75B(m)(m)$1.62B$117.00M$375.00M
2013-12-31$5.07B(m)(m)(m)(m)$589.00M
2013-09-30$4.80B(m)(m)$1.61B-$163.00M$966.00M
2013-06-30$4.93B(m)(m)$1.71B$125.00M$476.00M
2013-03-31$4.85B(m)(m)$1.79B$10.00M$545.00M
2012-12-31$5.63B(m)(m)(m)(m)$1.05B
2012-09-30$5.26B(m)(m)$1.92B-$107.61M$1.94B
2012-06-30$5.31B(m)(m)$1.81B$118.66M$1.73B
2012-03-31$5.28B(m)$50.00M$1.84B$112.16M$1.24B
2011-12-31$10.38B(m)(m)(m)(m)(m)
2011-09-30$9.82B(m)(m)$4.24B$198.41M(m)
2011-06-30$9.62B(m)(m)$2.76B-$268.23M(m)
2011-03-31$9.04B(m)(m)$2.85B$204.97M(m)
2010-12-31$9.97B(m)(m)(m)(m)(m)
2010-09-30$8.67B(m)(m)$2.67B$173.45M(m)
2010-06-30$8.83B(m)(m)$2.74B$267.04M(m)
2010-03-31$7.70B(m)(m)$2.16B$319.19M(m)
2009-12-31$8.79B(m)(m)(m)(m)(m)
2009-09-30$7.76B(m)(m)$2.09B$391.01M(m)
2009-06-30$7.49B(m)(m)$2.02B$278.93M(m)
2009-03-31$6.72B(m)(m)$2.07B$493.84M(m)
2008-12-31$7.95B(m)(m)(m)(m)(m)
2008-09-30$7.50B(m)(m)$2.07B$288.42M(m)
2008-06-30$7.31B(m)(m)$2.05B$314.30M(m)
2008-03-31$6.77B(m)(m)(m)(m)(m)

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-06-30$21.50B$9.32B$1.44B$6.15B$824.00M$3.10B
2024-06-30$20.34B$9.07B$1.38B$5.89B$516.00M$2.53B
2023-06-30$19.73B$8.81B$1.37B$5.50B$505.00M$2.69B
2022-06-30$23.15B$9.92B$1.38B$5.54B$763.00M$4.46B
2021-06-30$20.68B$9.35B$1.31B$5.51B$409.00M$2.98B
2020-06-30$15.05B$6.54B$1.14B$4.82B$78.00M$1.10B
2019-06-30$15.51B$6.44B$1.25B$4.91B$56.00M$1.68B
2018-06-30$15.16B$6.35B$1.16B$5.01B$81.00M$1.15B
2017-06-30$12.97B$6.25B(m)$4.59B$375.00M$702.00M
2016-06-30$10.22B(m)(m)$3.44B$62.00M$931.00M
2015-06-30$10.07B(m)(m)$3.46B$324.00M$3.08B
2014-06-30$9.81B(m)(m)$3.27B$350.00M$841.00M
2013-06-30$10.82B(m)(m)$3.50B$134.00M$1.02B
2012-06-30$10.60B(m)(m)$3.66B$230.82M(m)
2011-06-30$18.66B(m)(m)$5.61B-$63.26M(m)
2010-06-30$16.52B(m)(m)$4.91B$586.23M(m)
2009-06-30$14.21B(m)(m)$4.10B$772.77M(m)
2008-06-30$14.08B(m)(m)$4.07B$537.16M(m)

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-09-30$32.87B$14.40B$2.21B$9.20B$1.36B$4.75B
2024-09-30$30.98B$13.76B$2.10B$8.79B$810.00M$4.17B
2023-09-30$29.87B$13.42B$2.04B$8.22B$740.00M$4.13B
2022-09-30$33.56B$14.55B$2.16B$8.28B$1.09B$5.90B
2021-09-30$31.61B$13.77B$1.98B$8.28B$802.00M$5.08B
2020-09-30$23.91B$10.51B$1.72B$7.13B$267.00M$2.33B
2019-09-30$23.59B$9.80B$1.84B$7.35B$199.00M$2.64B
2018-09-30$22.81B$9.52B$1.74B$7.38B$247.00M$1.71B
2017-09-30$19.80B$9.13B(m)$6.71B$440.00M$1.30B
2016-09-30$15.52B(m)(m)$5.06B$240.00M$602.00M
2015-09-30$15.22B(m)(m)$5.13B$442.00M$3.66B
2014-09-30$14.89B(m)(m)$4.86B$627.00M$1.38B
2013-09-30$14.64B(m)(m)$4.83B-$71.00M$1.99B
2012-09-30$15.86B(m)(m)$5.58B$123.21M(m)
2011-09-30$28.47B(m)(m)$9.85B$135.16M(m)
2010-09-30$25.20B(m)(m)$7.58B$759.68M(m)
2009-09-30$21.97B(m)(m)$6.18B$1.16B(m)
2008-09-30$21.58B(m)(m)$6.14B$825.59M(m)

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$44.33B$19.32B$2.94B$12.33B$1.94B$6.52B
2024-12-31$41.95B$18.71B$2.84B$11.70B-$6.39B$13.40B
2023-12-31$40.11B$17.98B$2.74B$10.95B$941.00M$5.72B
2022-12-31$43.65B$19.14B$2.89B$11.25B$1.37B$6.93B
2021-12-31$43.08B$18.54B$2.74B$11.32B$1.14B$7.07B
2020-12-31$34.61B$15.00B$2.42B$9.70B$497.00M$4.50B
2019-12-31$31.90B$13.23B$2.44B$9.77B$390.00M$3.69B
2018-12-31$30.58B$12.71B$2.30B$9.74B$539.00M$2.37B
2017-12-31$27.39B$12.41B$2.26B$9.18B$1.88B$477.00M
2016-12-31$20.85B$9.09B(m)$6.74B$350.00M$1.40B
2015-12-31$20.41B(m)(m)$6.79B$577.00M$4.42B
2014-12-31$20.25B(m)(m)$6.53B$797.00M$2.28B
2013-12-31$19.66B(m)(m)$6.37B$53.00M$2.58B
2012-12-31$19.05B(m)(m)$6.74B-$457.00M$5.96B
2011-12-31$21.41B(m)(m)$7.37B$110.00M$4.73B
2010-12-31$35.17B(m)(m)$10.38B$1.09B(m)
2009-12-31$30.76B(m)(m)$8.41B$1.45B(m)
2008-12-31$29.53B(m)(m)$8.44B$1.12B(m)
2007-12-31$25.91B(m)(m)$7.41B$863.33M(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64